Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery.
Hsiang Ying LeeHann-Chorng KuoPublished in: Toxins (2023)
Although intravesical injection of BTX-A was a good option for controlling refractory OAB in men, the evidence-based guidelines are still limited. Further research is necessary to better understand the role of BTX-A injections on various aspects and histories. Therefore, treating patients using strategies tailored to their individual conditions is important.
Keyphrases
- botulinum toxin
- end stage renal disease
- prostate cancer
- ultrasound guided
- newly diagnosed
- urinary tract
- ejection fraction
- chronic kidney disease
- minimally invasive
- spinal cord injury
- middle aged
- muscle invasive bladder cancer
- peritoneal dialysis
- prognostic factors
- clinical practice
- patient reported outcomes
- smoking cessation
- platelet rich plasma